Anti-metastatic Profiles of Boesenbergia pandurata towards MCF-7/HER2 Cells

Hilyatul Fadliyah, Nindya Budiana Putri, Ziana Walidah, Ika Putri Nurhayati, Muthi Ikawati, Edy Meiyanto

Abstract


The development of breast cancer at an advanced stage is signed with metastatic phenomenon, triggering the high mortality, mainly for Human Epidermal Growth Factor Receptor (HER)2 positive cancers. Boesenbergia pandurata is well known as medicinal plant possessing anticancer potential due to the cytototoxic and antimetastatic characteristic of its active compound. The aim of this study is to observe the inhibitory effect of Boesenbergia pandurata ethanolic extract (BPEE) in combination with doxorubicin on migration of MCF-7/HER2 cells. The BPEE was prepared by 96% ethanol maceration. Under MTT assay, BPEE decreased the cells viability with IC50 value of 23±3.9 μg/mL. Lamellipodia and wound healing assay analysis showed that 5 μg/mL BPPE and its combination with 10 nM doxorubicin inhibited cells migration after 48 hours observation, while gelatin zymography analysis showed that this combination did not affect the expression of Matrix Metalloproteinase (MMP)2 and MMP9, but single treatment of 5 μg/mL BPEE caused lower expression of both MMPs. The combination of 5 μg/mL BPPE and 10 nM doxorubicin inhibited the cells migration but not affect to the cells viability. Thus, BPEE is potential to be developed as an antimetastatic agent. The mechanism underlying the migratory inhibition effect needs to be explored further.

Keywords : Boesenbergia pandurata, doxorubicin, MCF-7/HER2, migration
Submitted:


Full Text:

PDF

References


Amalina, N.D., Nurhayati, I.P. and Meiyanto, E., 2017, Doxorubicin Induces Lamellipodia Formation and Cell Migration, Indones. J. Cancer Chemoprevent., 8(2), 61-67, CrossRef.

Ansari, L., Shiehzadeh, F., Taherzadeh, Z., Nikoofal-Sahlabadi, S., Momtazi-Borojeni, A.A., Sahebkar, A., et al., 2017, The Most Prevalent Side Effects of Pegylated Liposomal Doxorubicin Monotherapy in Women with Metastatic Breast Cancer: A Systematic Review of Clinical Trials, Cancer Gene Ther., 24(5), 189-193, CrossRef.

ASCO, 2014, Side Effect of Chemotherapy, http://www.cancer.net/navigating-cancer-care/howcancer-treated/chemotherapy/side-effectschemotherapy, accessed May 11, 2015.

Bandyopadhyay, A., Wang, L., Agyin, J., Tang, Y., Lin, S., Yeh, I.T., et al., 2010, Doxorubicin in Combination with A Small TGFb Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models, PloS one, 5(4), e10365, CrossRef.

Batist, G., Harris, L., Azarnia, N., Lee, L.W. and Daza-Ramirez, P., 2006, Improved Anti-tumor Response Rate with Decreased Cardiotoxicity of Non-pegylated Liposomal Doxorubicin Compared with Conventional Doxorubicin in First-line Treatment of Metastatic Breast Cancer in Patients who Had Received Prior Adjuvant Doxorubicin: Results of A Retrospective Analysis, Anticancer Drugs, 17(5), 587-595, CrossRef.

Chahyadi, A., Hartati, R. and Wirasutisna, K.R., 2014, Boesenbergia Pandurata Roxb., An Indonesian Medicinal Plant: Phytochemistry, Biological Activity, Plant Biotechnology, Procedia Chem., 13, 13-37, CrossRef.

Chiang, A.C. and Massagué, J., 2008, Molecular Basis of Metastasis, N. Engl. J. Med., 359(26), 2814-2823, CrossRef.

Engel, R.H. and Kaklamani, V.G., 2007., HER2-positive Breast Cancer, Drugs, 67(9), 1329-1341, CrossRef.

Hulkower, K.I. and Herber, R.L., 2011, Cell Migration and Invasion Assays as Tools for Drug Discovery, Pharmaceutics, 3(1), 107-124, CrossRef.

Indonesian Ministry of Health, 2009, Keputusan Menteri Kesehatan No. 261/SK/MENKES/IV/2009 tentang Farmakope Herbal Indonesia Edisi Pertama, Jakarta: Indonesian Ministry of Health.

Kalluri, R. and Weinberg, R.A., 2009, The Basic of Epithelial-mesencymal Transition, J. Clin. Invest., 119(6), 1420-1428, CrossRef.

Kirana, C., Jones, G.P., Record, I.R. and McIntosh, G.H., 2007, Anticancer Properties of Panduratin A Isolated from Boesenbergia pandurata (Zingiberaceae), J. Nat. Med., 61(2), 131-137, CrossRef.

Lu, D.Y., Lu, T.R. and Wu, H.Y., 2013a, New Insights into Individualized Antimetastatic Therapy, Adv. Tech. Biol. Med., 1(1), 106, CrossRef.

Lai, S.L., Wong, P.F., Lim, T.K., Lin, Q. and Mustafa, M.R., 2015, ITRAQ-based Proteomic Identification of Proteins Involved in Antiangiogenic Effects of Panduratin A on HUVECs, Phytomedicine, 22(1), 203-212, CrossRef.

Mansel, R.E., Fodstad, O. and Jiang, W.G., 2007, Metastasis of Breast Cancer, New York: Springer, CrossRef.

Menendez, J.A., Mehmi, I. and Lupu, R., 2006, Trastuzumab in Combination With Heregulin-Activated Her-2 (erb B-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression, J. Clin. Oncol., 24(23), 3735-3746, CrossRef.

Mosmann, T., 1983, Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays, J. Immunol. Methods., 65(1-2), 55-63, CrossRef.

Prayong, P., Barusrux, S. and Weerapreeyakul, N., 2008, Cytotoxic Activity Screening of Some Indigenous Thai Plants, Fitoterapia, 79(7), 598-601, CrossRef.

Putri, D.D.P., Sarmoko, S., Febriansah, R., Puspitasari, E., Ismiyati, N. and Fitriasari, A., 2011, MCF-7 Resistant Doxorubicin are Characterized by Lamelapodia, Strong Adhesion on Substrate and P-gp Overexpression, Indones. J. Cancer Chemoprevent., 2(3), 304–309, CrossRef.

Seton-Rogers, S.E., Lu, Y., Hines, L.M., Koundinya, M., LaBaer, J., Muthuswamy, S.K., et al., 2004, Cooperation of the ErbB2 Receptor and Transforming Growth Factor b in Induction of Migration and Invasion in Mammary Epithelial Cells, Proc. Natl. Acad. Sci. USA, 101(5), 1257-1262, CrossRef.




DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev9iss2pp68-77

Copyright (c) 2018 Hilyatul Fadliyah, Nindya Budiana Putri, Ziana Walidah, Ika Putri Nurhayati, Muthi Ikawati, Edy Meiyanto

Indexed by:

               

                  

         

 

Indonesian Society for Cancer Chemoprevention